Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Supernus Pharmaceuticals receivables from 2011 to 2025. Receivables can be defined as the total amount of collectibles for a company

Supernus Pharmaceuticals Receivables 2011-2025 | SUPN

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Supernus Pharmaceuticals receivables from 2011 to 2025. Receivables can be defined as the total amount of collectibles for a company

Related Stocks
Company Name	Market Cap
Teva Pharmaceutical Industries (TEVA)	$15.5B
Dr Reddy's Laboratories (RDY)	$11.4B
BridgeBio Pharma (BBIO)	$6.4B
Bausch Health Cos (BHC)	$1.9B
Amphastar Pharmaceuticals (AMPH)	$1.1B
Personalis (PSNL)	$282M
Taysha Gene Therapies (TSHA)	$254M
Assembly Biosciences (ASMB)	$75M
Sol-Gel Technologies (SLGL)	$15M
Evoke Pharma (EVOK)	$3M
Teligent (TLGT)	$0M